Literature DB >> 11106752

Two critical hits for promyelocytic leukemia.

L Z He1, M Bhaumik, C Tribioli, E M Rego, S Ivins, A Zelent, P P Pandolfi.   

Abstract

Acute promyelocytic leukemia (APL) is associated with chromosomal translocations that always involve the RARalpha gene, which variably fuses to one of several distinct loci, including PML or PLZF (X genes). Due to the reciprocity of the translocation, X-RARalpha and RARalpha-X fusion proteins coexist in APL blasts. PLZF-RARalpha transgenic mice (TM) develop leukemia that lacks the differentiation block at the promyelocytic stage that characterizes APL. We generated TM expressing RARalpha-PLZF and PLZF-RARalpha in their promyelocytes. RARalpha-PLZF TM do not develop leukemia. However, PLZF-RARalpha/RARalpha-PLZF double TM develop leukemia with classic APL features. We demonstrate that RARalpha-PLZF can interfere with PLZF transcriptional repression and that this is critical for APL pathogenesis, since leukemias in PLZF(-/-)/PLZF-RARalpha mutants and in PLZF-RARalpha/RARalpha-PLZF TM are indistinguishable. Thus, both products of a cancer-associated translocation are crucial in determining the distinctive features of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106752     DOI: 10.1016/s1097-2765(00)00111-8

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  33 in total

Review 1.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

Review 3.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

4.  Mzf1 controls cell proliferation and tumorigenesis.

Authors:  M Gaboli; P A Kotsi; C Gurrieri; G Cattoretti; S Ronchetti; C Cordon-Cardo; H E Broxmeyer; R Hromas; P P Pandolfi
Journal:  Genes Dev       Date:  2001-07-01       Impact factor: 11.361

5.  Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level.

Authors:  Jihui Qiu; Ying Huang; Guoqiang Chen; Zhu Chen; David J Tweardy; Shuo Dong
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

6.  Functional antagonism between Sall4 and Plzf defines germline progenitors.

Authors:  Robin M Hobbs; Sharmila Fagoonee; Antonella Papa; Kaitlyn Webster; Fiorella Altruda; Ryuichi Nishinakamura; Li Chai; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

7.  8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.

Authors:  Bo Jiao; Zhi-Hong Ren; Ping Liu; Li-Juan Chen; Jing-Yi Shi; Ying Dong; Julien Ablain; Lin Shi; Li Gao; Jun-Pei Hu; Rui-Bao Ren; Hugues de Thé; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 8.  Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective.

Authors:  Danilo Maddalo; Andrea Ventura
Journal:  Cancer Res       Date:  2016-08-12       Impact factor: 12.701

Review 9.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

10.  A feedback loop mediated by degradation of an inhibitor is required to initiate neuronal differentiation.

Authors:  Dorothy F Sobieszczuk; Alexei Poliakov; Qiling Xu; David G Wilkinson
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.